EN | JPN | FR
EN | JPN | FR
Ceaselessly refining our research to set the bar higher.
Over the last 45+ years, Ora has been at the forefront of supporting our customers in developing innovative products for the treatment of allergic conjunctivitis, blepharitis, and similar conditions.
We are driven to bring better research models to you, providing you with more reproducible, clearer data. Ora’s team of allergy experts has supported the clinical development of 17 anti-allergic agents for the treatment of allergic conjunctivitis. Our experience in both challenge and environmental trials will help bring your product to market.
Ocular Redness as seen on the Sclera
Since joining Ora in 1998, Paul Gomes has ascended to Vice President of Allergy & Blepharitis. Leading a team of 28, he collaborates with clients to develop efficient clinical development strategies for products, offering regulatory guidance, clinical study design, data analysis, and marketing advice, while also ensuring profitability.
Paul has directed the execution and design of protocols, managed multi-center trials globally, and consistently liaised with regulatory bodies in Europe, Japan, and the US.
His oversight extends across the development lifecycle of numerous products, from initial proof of concept to Phase IV, including brands like Zaditen®, Pataday®, Lumify®, Dextenza®, ACUVUE® Theravision® with Ketotifen and many others, ensuring their effectiveness, safety, and managing pharmacokinetic and marketing studies.
VP of Allergy & Blepharitis
For decades, the Ora Conjunctival Challenge Model (Ora-CAC®) has been used to evaluate every anti-allergic agent for the treatment of allergic conjunctivitis and are the gold standard for FDA approval of ocular allergy treatments.
While environmental studies continue to be used for the assessment of anti-allergic agents, the precision of the Ora-CAC® model study design allows for a more predictive and rapid study, with fewer patients, fewer sites, and a tighter dataset.
The Allergen BioCube® is Ora’s proprietary clinical model used in trials for allergic rhinitis and conjunctivitis. It is a versatile allergen exposure chamber that can be stationary or mobile, meticulously releasing measured pollen amounts for consistent and controlled exposure. It’s effective for solo use or combined with other models to confirm the efficacy of treatments in critical studies.
In simulating pollen exposure, Ora ensures accuracy with real-time laser detection of airborne aeroallergens, creating an exposure experience that mirrors natural conditions, triggering real allergy symptoms in patients.
Ora, Inc websites use cookies. By continuing to browse the site you are agreeing to our use of cookies.
For more details about cookies and their use, please see our Privacy Policy.
